You are here

Exploiting Microbiome and Synthetic Biology to Discover and Produce Naturally Occurring Antibiotics

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-16-P-0050
Agency Tracking Number: C152-004-0089
Amount: $149,877.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD152-004
Solicitation Number: 2015.2
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-29
Award End Date (Contract End Date): 2017-02-28
Small Business Information
2430 5th St.Ste. D
Berkeley, CA 94710
United States
DUNS: 078535589
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dr. Jeffrey Kim
 (510) 621-7332
 jeff@radiantgenomics.com
Business Contact
 Oliver Liu
Title: Dr.
Phone: (510) 621-7332
Email: oliver@radiantgenomics.com
Research Institution
N/A
Abstract

In this proposal, we aim to validate the human gut microbiome and arid soil as a source of antibiotic natural products (NPs ) by using ametagenomic NP discovery platform developed at Radiant Genomics. Recent studies suggest that the genomes of uncultivated microorganisms,like their cultivated counterparts, encode an enormous number of NPs. Gaining systematic access to NPs using standard, cultivation-dependentapproaches, however, remains challenging as <1% of microbial diversity has been successfully cultured in a laboratory setting. In the interest ofexpanding the list of currently-available antibiotic pharmacophores, our company has built a metagenomic platform (which overcomes cultivationbarriers) for discovering, producing, and diversifying NPs from complex microbiomes. At its core, this platform consists of a world-class pipeline forsequencing, assembling, refactoring, and expressing full-length NP gene clusters from complex environments, including uncultivated microbes.Our system identifies NP-encoding gene clusters using both a sequence-guided search engine and a droplet microfluidics-based antibacterialscreening technology that has capacity to analyze >10^7 clones/day. Because our libraries are renewably cloned, we can rapidly isolate,assemble, refactor and heterologously express selected gene clusters in our panel of metabolically-optimized, gram(+ and -) industrial hoststrains, resulting in high-throughput, systematic identification of novel NPs.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government